You are here
Press Release Archive
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 26. To access the Webcast, visit our Website at www.pfizer.com and click on the “Webcast of the Annual Meeting” link under the “Annual Meeting of Shareholders” section. Pre-registration for the Webcast will be available at that linkmore
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web site homepage
(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges stemming from the off-label marketing of Genotropin — a human growth hormone medicine — and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before that
(BUSINESS WIRE) Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology. “One of these analyses suggests that even with the availability of low
(BUSINESS WIRE) Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heart
(BUSINESS WIRE) Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting of
(BUSINESS WIRE) In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company’s Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six
(BUSINESS WIRE) Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and strokes, and health economics will be presented next week at the American College of Cardiology annual meeting in New Orleans. Atherosclerosis Imaging Trials Three large imaging studies compared Pfizer’s former investigational compound
(BUSINESS WIRE) Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the company’s U.S. patent covering amlodipine besylate, the active ingredient in Norvasc. Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration. Generic manufacturer Apotex filed the appeal after a lower
(BUSINESS WIRE) Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. Judge John C. Lifland ruled that the patents (Nos. 5,466,823; 5,563,165
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.